Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

TP-0184 Inhibits ALK2/ACVR1, Decreases Hepcidin Levels, and Demonstrates Activity in Preclinical Mouse Models of Functional Iron Deficiency

Peter Peterson, PhD, W K, Clifford Whatcott, PhD, Adam Siddiqui-Jain, PhD, Steven Weitman, MD PhD, Mark Kieran, MD PhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2017) 130 (Supplement 1): 937.

https://doi.org/10.1182/blood.V130.Suppl_1.937.937

Published: 2017

Journal Articles

Overexpression of BRD4 Is an Adverse Prognostic Factor in Acute Myeloid Leukemia

Hima Bansal, Steven Kornblau, MD, Qiu Yihua, Kevin R Coombes, Subbarayalu Panneerdoss, Anand Karnad, MD, Steven Weitman, MD PhD, Gail Tomlinson, MD PhD, Sanjay Bansal, Swami P. Iyer, MD

Blood (2017) 130 (Supplement 1): 3794.

https://doi.org/10.1182/blood.V130.Suppl_1.3794.3794

Published: 2017

Journal Articles

Alvocidib Potentiates the Activity of Venetoclax in Preclinical Models of Acute Myeloid Leukemia

Clifford J. Whatcott, PhD, James M Bogenberger, PhD, Wontak Kim, Hillary Haws, Nanna Hansen, M.S., Devora Delman, B.S., Lisa Sproat, MD MSW, Jeanne Palmer, MD, Ruben A. Mesa, MD, Peter Peterson, PhD, Adam Siddiqui-Jain, PhD, Steven Weitman, MD PhD, David J. Bearss, PhD, Steven L. Warner, PhD, Raoul Tibes, MD PhD

Blood (2016) 128 (22): 1652.

https://doi.org/10.1182/blood.V128.22.1652.1652

Published: 2016

Journal Articles

Phase II Trials of Clofarabine in Relapsed or Refractory Pediatric Leukemia.

Sima Jeha, MD, Bassem I. Razzouk, MD, Michael E. Rytting, MD, Paul S. Gaynon, MD, Richard Kadota, MD, Susan Rheingold, MD, Lori Luchtman-Jones, MD, Violet Shen, MD, Robert J. Arceci, MD, PhD, Manuel Fernandez, B.S., Steven Weitman, MD, PhD, Peter G. Steinherz, MD

Blood (2004) 104 (11): 684.

https://doi.org/10.1182/blood.V104.11.684.684

Published: 2004

Journal Articles

Preliminary Safety and Efficacy Report of a Randomized Trial of Alemtuzumab vs Chlorambucil as Front-Line Therapy in 297 Patients with Progressive B-Cell Chronic Lymphocytic Leukemia.

Peter Hillmen, MB ChB, PhD, Aleksander B. Skotnicki, MD, PhD, Tadeusz Robak, MD, PhD, Jiri Mayer, MD, PhD, Branimir Jaksic, MD, PhD, Vojo Vukovic, MD, PhD, Steven Weitman, MD, PhD

Blood (2004) 104 (11): 2505.

https://doi.org/10.1182/blood.V104.11.2505.2505

Published: 2004

NARROW

TP-0184 Inhibits ALK2/ACVR1, Decreases Hepcidin Levels, and Demonstrates Activity in Preclinical Mouse Models of Functional Iron Deficiency

Overexpression of BRD4 Is an Adverse Prognostic Factor in Acute Myeloid Leukemia

Alvocidib Potentiates the Activity of Venetoclax in Preclinical Models of Acute Myeloid Leukemia

Phase II Trials of Clofarabine in Relapsed or Refractory Pediatric Leukemia.

Preliminary Safety and Efficacy Report of a Randomized Trial of Alemtuzumab vs Chlorambucil as Front-Line Therapy in 297 Patients with Progressive B-Cell Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

TP-0184 Inhibits ALK2/ACVR1, Decreases Hepcidin Levels, and Demonstrates Activity in Preclinical Mouse Models of Functional Iron Deficiency

Overexpression of BRD4 Is an Adverse Prognostic Factor in Acute Myeloid Leukemia

Alvocidib Potentiates the Activity of Venetoclax in Preclinical Models of Acute Myeloid Leukemia

Phase II Trials of Clofarabine in Relapsed or Refractory Pediatric Leukemia.

Preliminary Safety and Efficacy Report of a Randomized Trial of Alemtuzumab vs Chlorambucil as Front-Line Therapy in 297 Patients with Progressive B-Cell Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only